← All trials
NCT00928187
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2009
- Primary completion
- Sep 1, 2013
- Completion date
- Dec 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 454
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- French National Agency for Research on AIDS and Viral HepatitisLead sponsor
- CHU Fann DakarOverall official - principal investigator
- University of YaoundeOverall official - principal investigator
- Gilead SciencesCollaborator
- CHU Sanou Souro, Bobo-DioulassoOverall official - principal investigator
- Janssen Pharmaceutica NVCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.